Mohs Surgery, Hour by Hour: Why You Spend the Day Waiting, and Why That's the Point

The waiting is the procedure

Almost everything unusual about a Mohs day is organisational rather than surgical. The removal itself takes a few minutes. The stitching, when it comes, takes longer than the cutting. What consumes the day is the gap between them, and patients are rarely told clearly enough that the gap is the entire reason the operation works.

Here is the problem Mohs solves. A skin cancer is not the shape it looks. What you can see on the surface is the visible part of something that may send irregular extensions sideways under intact-looking skin or downwards along tissue planes. A surgeon looking at that lesion has to guess how far it goes.

Standard excision handles this by taking a predicted margin — a few millimetres of clinically normal-looking skin all round — closing the wound, and sending the specimen to a pathology laboratory. The pathologist samples that specimen in slices, examining a fraction of the true margin, and a report arrives days later. If it says the margin was involved, you come back and have more taken from a wound that has already been closed.

Mohs replaces prediction with measurement. A thin layer is removed, oriented, mapped, and processed so that essentially the whole surgical margin — the deep surface and the entire peripheral edge — is examined in one plane. The surgeon, who is also reading the slides, can then say not merely whether tumour remains but where on the map it remains, and return to that point alone.

That is why you wait. The tissue is being turned into slides while you sit down the corridor, and the answer determines whether the day is over.

What the evidence shows, and where it stops short

Mohs is generally regarded as offering the best margin control available for the tumours it is used on, and the strongest evidence is a randomised trial worth quoting precisely rather than in summary.

Between 1999 and 2002, investigators randomised 408 primary high-risk facial basal cell carcinomas and 204 recurrent facial basal cell carcinomas to either standard surgical excision or Mohs, and followed them for ten years. High-risk meant a diameter of at least a centimetre, a location in the so-called H-zone of the face, or an aggressive histological subtype.

For primary tumours, the ten-year cumulative probability of recurrence was 4.4 percent after Mohs and 12.2 percent after standard excision. That is a substantial absolute difference — and it did not reach statistical significance. For recurrent tumours, the figures were 3.9 percent and 13.5 percent, and that difference was significant.

Both halves of that deserve stating. The trial supports Mohs most strongly where the tumour has already come back once, which is intuitive: a recurrent tumour sits in scarred, distorted tissue where predicting a margin is hardest. For primary high-risk tumours the direction of effect favours Mohs clearly and the statistics stopped short of confirming it, which is a reason for honest language rather than for dismissing either the technique or the finding.

The number from that trial with the most direct consequence for a patient is a different one. Fifty-six percent of the primary basal cell carcinoma recurrences occurred more than five years after treatment. More than half. Which means a five-year all-clear is not the end of the story, and the authors said so explicitly — long-term follow-up matters for high-risk facial tumours in a way that shorter surveillance protocols do not capture. If you have had one skin cancer, the single most useful thing you can do is keep going to skin checks after the point at which you feel finished. Our skin cancer risk tool sets out what raises your baseline, and the mole map is worth starting if you have not.

The day, in order

Timings vary by unit, but the shape is consistent enough to plan around.

You arrive in the morning. The site is confirmed and marked — expect to be asked repeatedly to confirm which lesion, which is a safety check rather than disorganisation. Then local anaesthetic is injected around the site.

The first stage takes minutes. A thin, saucer-shaped layer is removed, with a very narrow margin rather than the wider one a standard excision would take, and the specimen is oriented and marked so its edges can be related back to your face. A pressure dressing goes on, and you return to the waiting area.

Then the long part. In the laboratory the specimen is divided, colour-coded, flattened and frozen, cut on a cryostat into sections that capture the full margin in one plane, mounted and stained. The surgeon reads them. This typically takes something in the region of forty-five minutes to an hour and a half per stage, and there is no way to hurry it — the freezing and sectioning steps have their own physics.

If the margin is clear, you move to repair. If tumour remains, the map shows where, more anaesthetic goes in, and another layer is taken from that area alone. Most cases clear within one to three stages, but there is no guarantee, and this is why nobody can tell you in advance what time you will leave.

Practical consequences: bring something to occupy several hours, bring food if the unit allows it, arrange for someone to accompany you home if a large repair is likely, and do not schedule anything for the afternoon. A dressing on your face and a half-finished procedure is not a state to attend a meeting in. Our derm visit prep tool covers the questions worth writing down beforehand, and it is worth asking specifically whether your unit runs one or multiple cases in parallel, since that changes the waiting rhythm considerably.

Awake, numb, and what that actually feels like

Mohs is done under local anaesthetic. You are awake throughout, and this surprises people more than any other feature of the day.

What you feel is the injection: a sting and a burning sensation for several seconds, sometimes described as worse than expected, followed by a spreading numbness. After that you feel pressure, movement and tugging, but not cutting. Pressure sensation is not blocked by local anaesthetic, so the impression of something being done is entirely normal and is not a sign the anaesthetic has failed.

Between stages you sit with a dressing on, generally in an ordinary waiting room, generally alongside other people in the same position. Units differ on whether you can leave the building; many prefer you do not.

If more anaesthetic is needed for a second stage, the injection into already-numb tissue is usually far less uncomfortable than the first. Tell the team if you feel anything sharp — the answer is more anaesthetic, immediately, and nobody expects you to tolerate it.

Two specific things to raise beforehand rather than on the day. Anticoagulants and antiplatelet medicines are usually continued for dermatological surgery, but that decision belongs to your team and needs to be made in advance rather than in the chair. And if you have ever reacted to surgical dressings or tapes, say so at the planning appointment — adhesive and antiseptic allergies are common enough to matter and easy to work around when known, which ↗our answer on contact allergy and surgical adhesives covers in more detail.

Repair: four options, decided after clearance

The reconstruction conversation happens once the margin is clear, and that ordering is deliberate rather than evasive. Until the surgeon knows how much tissue had to come out, and in what shape, the repair cannot be planned. It is also why an honest surgeon will not promise you a specific scar in advance.

A linear closure pulls the wound edges together in a straight line, usually along a natural crease or relaxed skin tension line. It is the simplest option and produces the most predictable result when the defect is small enough and the surrounding skin is lax enough.

A flap moves adjacent skin into the defect while keeping its own blood supply. It is used when direct closure would distort something that must not be distorted — an eyelid, a nostril rim, a lip border. Flaps are more complex, involve longer incision lines than the defect itself, and are often the reason a scar looks larger at first than the hole it repaired.

A graft takes skin from elsewhere and lays it in without its own blood supply, relying on the wound bed to sustain it. It solves defects too large for local tissue, at the cost of a colour and texture mismatch that improves but rarely disappears, plus a second wound at the donor site.

And healing by second intention means leaving the wound open to close on its own, dressed and cleaned daily over weeks. Patients often hear this as being fobbed off, and it is not. A systematic review of patient satisfaction with second-intention healing after Mohs found it to be a well-regarded option, and in concave sites — the inner corner of the eye, the fold of the nostril, the bowl of the ear — it can produce a better result than a flap, because the healing tissue contracts into a shape that mimics the anatomy. It is slower and requires more of you in dressing changes. It is not a lesser choice.

Week one, month one, month six

Recovery has a shape that is worth knowing in advance, because the middle of it looks alarming to people who were not warned.

Week one is the messy one. Expect swelling, and expect it to be worse the morning after than on the day. Bruising around the eyes is common after work anywhere on the upper face and travels downward under gravity. There will be oozing early on. Pain is usually modest and manageable with simple analgesia; significant or increasing pain after the first couple of days is a reason to call the unit rather than to wait. Follow the dressing instructions your team gives you over anything in this article, but the general principle is that a wound heals better moist than dry, which is why a plain ↗petrolatum ointment such as Aquaphor Healing Ointment or CeraVe Healing Ointment under a dressing is the standard instruction rather than an antibiotic cream. Topical antibiotic ointments are a well-documented cause of allergic contact dermatitis on healing wounds, which is exactly the complication you do not want on a face.

Month one is when it looks worst and people worry most. Sutures come out within one to two weeks depending on site. The scar then goes through its inflammatory phase: firm, raised, pink or red, sometimes itchy, sometimes numb, occasionally all at once. This peaks somewhere around one to two months and it is a normal stage rather than a bad outcome. Around this point you can usually resume gentle cleansing of the area with something bland like Vanicream Gentle Facial Cleanser, once your team confirms the wound is closed.

Month six and beyond is where the actual result appears. Scars remodel for a year or more, flattening and fading gradually. Two things genuinely help during that window: sun protection, because ultraviolet exposure on immature scar tissue drives persistent redness and pigmentation, and time. A mineral sunscreen such as Vanicream Mineral Sunscreen is the usual recommendation on a new scar, mostly because it is well tolerated on skin that is still settling. Judge the outcome at a year, not at a month.

And the last thing, which is easy to skip in the relief of being finished: having had one keratinocyte skin cancer substantially raises the likelihood of another, and the sun damage that produced this one produced other changes too. ↗The actinic keratosis pathway covers the precancerous end of that spectrum and what treating it involves — because the most useful outcome of a Mohs day is not just the tumour that came out, but the surveillance that starts afterwards.